Endocrine Abstracts

Objectives: Lonapegsomatropin (SKYTROFA; TransCon hGH), a prodrug of somatropin, is approved by the EMA and FDA for once-weekly treatment of pediatric growth hormone deficiency (GHD). Lonapegsomatropin uses TransCon® technology, which combines a parent drug transiently linked to an inert carrier to achieve sustained release. The characterization of anti-drug antibodies (ADAs) was assessed in 3 phase 3 trials of lonapegsomatropin in pediatric GHD.Met...